2440 RESEARCH BLVD, ROCKVILLE, MD
Reports Clinical Data from Ongoing Phase 1 Clinical Trial of Ragistomig (Also Known as ABL503 or TJ-L14B)
Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
Appointment of Independent Director
Voting Results of 2026 Annual General Meeting
Company Presentation August 2026
Condensed Consolidated Balance Sheets As of June 30, 2026 and December 31, 2025
Annual General Meeting of Shareholders
2026 Omnibus Share Incentive Plan
Amended Annual and Transition Report of Foreign Private Issuers
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Registration Statement for Depositary Shares, Issued upon Effectiveness
Submission Upload
Correspondence